Advertisement
Advanced Search

To view the full text, please login as a subscribed user or purchase a subscription. Click here to view the full text on ScienceDirect.

Synthetic cannabinoid usage has increased in the past decade. Concurrently, emergency management of associated adverse effects due to synthetic cannabinoid usage has also risen. Reported toxicities include psychosis, seizures, cardiotoxicity, acute kidney injury, and death. While cannabis was first described as a cause of acute hyperemesis in 2004, a more recent case series also describes the association between cannabinoid hyperemesis and risk of acute renal failure. Synthetic cannabinoids have also been reported to cause acute hyperemesis and acute renal failure; however, the risk of rhabdomyolysis-induced renal failure has yet to be elucidated.

To access this article, please choose from the options below

Log In


Forgot password?

Register

Create a new account

Purchase access to this article

Claim Access

If you are a current subscriber with Society Membership or an Account Number, claim your access now.

Subscribe to this title

Purchase a subscription to gain access to this and all other articles in this journal.

Institutional Access

Visit ScienceDirect to see if you have access via your institution.

Funding: No external support provided.

☆☆Conflicts of interest: No conflicts of interest to disclose.

Related Articles

Searching for related articles..

Advertisement